Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,950.00
-70.00 (-1.39%)
At close: Jun 19, 2026

Seoulin Bioscience Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
78,58577,09175,41089,569104,70880,539
Other Revenue
--0-0---
78,58577,09175,41089,569104,70880,539
Revenue Growth (YoY)
5.38%2.23%-15.81%-14.46%30.01%23.74%
Cost of Revenue
61,38259,81056,45069,69980,41759,469
Gross Profit
17,20317,28218,96119,87124,29221,070
Selling, General & Admin
13,95114,01014,69715,01612,47511,144
Research & Development
809.16935.021,214785.23870.46786.82
Amortization of Goodwill & Intangibles
81.0681.4592.26112.83163.33459.01
Other Operating Expenses
505.58467.42483.24441.22396.47382.27
Operating Expenses
16,43416,59018,00817,37615,09413,619
Operating Income
769.1691.62952.672,4959,1987,451
Interest Expense
-971.39-644.56-329.7-2,482-2,287-224.55
Interest & Investment Income
837.5743.58996.222,0511,637303.78
Earnings From Equity Investments
21.517.5488.5385.1121.01114.5
Currency Exchange Gain (Loss)
-121.69-138.910.01-308.95-63.7-178.86
Other Non Operating Income (Expenses)
943.871,025666.373,4413,808-397.15
EBT Excluding Unusual Items
1,4791,6842,3845,28012,4137,069
Gain (Loss) on Sale of Investments
-453.02-421.131,986-4,9662,011160.11
Gain (Loss) on Sale of Assets
-0-0-13.69-31.42-1.0614,153
Asset Writedown
-373.89-373.89-152.6--393.03-1,044
Other Unusual Items
---648.11-2,211--
Pretax Income
651.99888.93,556-1,92914,02920,338
Income Tax Expense
217.36315.15415.34394.293,4644,459
Earnings From Continuing Operations
434.63573.753,140-2,32310,56515,879
Earnings From Discontinued Operations
----29.47-111.04
Net Income to Company
434.63573.753,140-2,32310,59515,768
Minority Interest in Earnings
83.54158.23-226.342,206-435.72-178.88
Net Income
518.17731.982,914-117.5510,15915,589
Net Income to Common
518.17731.982,914-117.5510,15915,589
Net Income Growth
-80.99%-74.88%---34.84%218.64%
Shares Outstanding (Basic)
999999
Shares Outstanding (Diluted)
101099119
Shares Change (YoY)
11.59%10.81%-2.96%-19.46%23.72%-0.07%
EPS (Basic)
59.9484.82335.00-13.111131.841733.06
EPS (Diluted)
32.7755.00335.00-13.11780.071732.89
EPS Growth
-89.60%-83.58%---54.98%218.90%
Free Cash Flow
975.24,367-4,660-14.95-4,8177,984
Free Cash Flow Per Share
101.02453.09-535.72-1.67-432.86887.61
Gross Margin
21.89%22.42%25.14%22.18%23.20%26.16%
Operating Margin
0.98%0.90%1.26%2.79%8.78%9.25%
Profit Margin
0.66%0.95%3.86%-0.13%9.70%19.36%
Free Cash Flow Margin
1.24%5.67%-6.18%-0.02%-4.60%9.91%
EBITDA
1,9171,8552,3183,78110,2159,381
EBITDA Margin
2.44%2.41%3.07%4.22%9.75%11.65%
D&A For EBITDA
1,1481,1631,3651,2871,0171,930
EBIT
769.1691.62952.672,4959,1987,451
EBIT Margin
0.98%0.90%1.26%2.79%8.78%9.25%
Effective Tax Rate
33.34%35.45%11.68%-24.69%21.92%
Advertising Expenses
-348.51357.36227.45119.05141.61